Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Inhibitors support immune therapy for leukaemia

New immune therapies are considered a promising lead for treating recurring acute myeloid leukaemia (AML).

Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies.

Scientists from the German Cancer Consortium (DKTK) and the Munich University Hospital and Tübingen University Hospital have shown that, in conjunction with certain inhibitors, this form of therapy could be successful in even more patients.

In the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ) in Heidelberg joins up as a core centre in long-term collaborations with partner university institutes and hospitals all over Germany that are specialised in research and treatment with a focus on oncology.

Acute Myeloid Leukaemia (AML) is a malignant blood cancer variety, which derives from the immature precursors of red blood cells, platelets, and some white blood cells.

AML is the most common acute leukaemia in adults.

For about a third of patients the cause of the uncontrolled cell division of the malignant cells is a mutation of the growth receptor FLT3.

This is why cancer medicine pursues a variety of strategies in attacking this mutated receptor therapeutically, such as with inhibitors or antibodies in cancer immune therapy.

One such antibody was recently developed in the German Cancer Consortium (DKTK) and is now undergoing clinical trials at the Tübingen University Hospital.

The FLT3 antibody marks leukaemia cells which remain in the body after a seemingly successful chemotherapy.

The marked blood cancer cells are then recognised by the body's own immune cells and will be eliminated.

"Immune therapy solely with the FLT3 antibody, however, is not always successful", explains Philipp Greif, DKTK junior group leader at Munich University Hospital (LMU)."

In some cases the FLT3 receptor has mutated so much, that it has largely disappeared from the surface of the leukaemia cell and is therefore no longer accessible to the antibody.

In a collaborative study, both the Tübingen and Munich scientists examined the possibility of successfully treating AML via a combination of both substances.

They used special inhibitors, so-called kinase inhibitors, in order to bring the mutated FLT3 receptor back to the surface in order to make it susceptible to immune therapy again. This way, more AML cells were able to be eliminated.

"The combination of both treatments worked much better in our pre-clinical trials than just one active substance", said Katrin Reiter, first author of the study.

Both FLT3 inhibitors and FLT3 antibodies are quite advanced in clinical trials.

Recently the FLT3 inhibitor midostaurin was approved for use in combination with standard chemotherapy.

Follow-up studies will now be conducted to determine which of the available inhibitors are the most suitable to be combined with the FLT3-based immune therapy.

Source: German Cancer Research Center



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation